Literature DB >> 1376769

Antipeptide antisera define neutralizing epitopes on the adenovirus hexon.

C I Toogood1, J Crompton, R T Hay.   

Abstract

The adenovirus (Ad) hexon contains both group-and type-specific antigenic determinants. To identify the latter, peptides were synthesized corresponding to residues 281 to 292 from loop 1 and 441 to 455 from loop 2 of the Ad2 hexon. These sequences display type-specific variation and have been shown by X-ray crystallography to be present on the surface of the virion. Antisera raised against the peptides bound both peptide and the native hexon in ELISA, and blocked virus infectivity, as determined by immunofluorescence or neutralization assays. The loop 1 peptide was shown to inhibit binding of the corresponding antiserum to the native hexon in ELISA and to abolish its neutralizing activity. Neither the loop 1- nor loop 2-specific antiserum neutralized the infectivity of Ad4 or Ad40. Neutralization did not appear to result from aggregation of virus particles and thus their inability to attach to the cell, because virions treated with immune serum were internalized to the same extent as those treated with preimmune serum. Examination of the immune response elicited by Ad2 infection revealed that antibodies directed against the L1 and L2 epitopes were also present in human serum. Thus, the variable regions exposed on the surface of the Ad2 hexon represent type-specific neutralizing antigenic determinants.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1376769     DOI: 10.1099/0022-1317-73-6-1429

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  39 in total

1.  The subgenus-specific C-terminal region of protein IX is located on the surface of the adenovirus capsid.

Authors:  A Akalu; H Liebermann; U Bauer; H Granzow; W Seidel
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Authors:  Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Wouter Koudstaal; Maria G Pau; Stefan Kostense; Menzo J E Havenga; Jaap Goudsmit; Norman L Letvin; Dan H Barouch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.

Authors:  Edward Nwanegbo; Eftyhia Vardas; Wentao Gao; Hilton Whittle; Huijie Sun; David Rowe; Paul D Robbins; Andrea Gambotto
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

4.  Regulation of virus neutralization and the persistent fraction by TRIM21.

Authors:  W A McEwan; F Hauler; C R Williams; S R Bidgood; D L Mallery; R A Crowther; L C James
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 5.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

6.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Structure-based identification of a major neutralizing site in an adenovirus hexon.

Authors:  Susan L Pichla-Gollon; Mark Drinker; Xiangyang Zhou; Feng Xue; John J Rux; Guang-Ping Gao; James M Wilson; Hildegund C J Ertl; Roger M Burnett; Jeffrey M Bergelson
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

8.  Preparation and evaluation of chicken embryo-adapted fowl adenovirus serotype 4 vaccine in broiler chickens.

Authors:  Muhammad Khalid Mansoor; Iftikhar Hussain; Muhammad Arshad; Ghulam Muhammad
Journal:  Trop Anim Health Prod       Date:  2010-09-28       Impact factor: 1.559

9.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Optimizing atoh1-induced vestibular hair cell regeneration.

Authors:  Hinrich Staecker; Christina Schlecker; Shannon Kraft; Mark Praetorius; Chi Hsu; Douglas E Brough
Journal:  Laryngoscope       Date:  2014-06-17       Impact factor: 3.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.